Abstract
In a laboratory setting, regenerative medicine has proven its potential to revolutionize modern medicine. The translational science model is designed to drive scientific discoveries out of the laboratory and into routine clinical practice from ‘the bench to the bedside.’ However, the reality of this process is that most innovations fail to achieve their desired clinical impact. Each step of translational process faces a unique set of barriers that require a significant amount of time, effort, and money to overcome. Despite these challenges, successful innovations have the potential to impact the lives of patients worldwide. With the appropriate knowledge and planning, the translational scientist can successfully bridge the gap between the basic scientist and the clinician, converting scientific breakthroughs into novel treatments and therapies for patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gehr S, Garner CC. Rescuing the lost in translation. Cell. 2016;165(4):765–70.
Milne CP, Kaitin KI. Translational medicine: an engine of change for bringing new technology to community health. Sci Translational Med. 2009;1(5):5cm5.
Fernandez-Moure JS. Lost in translation: the gap in scientific advancements and clinical application. Front Bioeng Biotechnol. 2016;4:43.
Butler D. Translational research: crossing the valley of death. Nature. 2008;453(7197):840–2.
Siegel DS, Veugelers R, Wright M. Technology transfer offices and commercialization of university intellectual property. Oxford Rev Econ Pol. 2007;23(4):640–60.
Tajonar A. How to start a biotech company. Mol Biol Cell. 2014;25(21):3280–3.
Mas JP, Hsueh AB. An investor perspective on forming and funding your medical device start-up. Tech Vasc Intervent Radiol. 2017;20(2):101–8.
Yock PG, Zenios S, Makower J, Brinton TJ, Kumar UN, Watkins FTJ, Denend L, Krummel TM, Kurihara CQ. Biodesign: the process of innovating medical technologies. 2nd ed. Cambridge: Cambridge University Press; 2015.
Kolchinsky P. Entrepreneur’s guide to a biotech startup. https://www.ldeming.com/s/Kolchinsky.pdf. Accessed 2 April 2018.
Naghshineh N, Brown S, Cederna PS, Levi B, Lisiecki J, D'Amico RA, Hume KM, Seward W, Rubin JP. Demystifying the U.S. Food and Drug Administration: understanding regulatory pathways. Plast Reconstr Surg. 2014;13(3):559–69.
Abou-El-Enein M, Duda GN, Gruskin EA, Grainger DW. Strategies for derisking translational processes for biomedical technologies. Trends Biotechnol. 2016;35(2):100–8.
Gompers P, Gornall W, Kaplan SN, Strebulaev IA. How do venture capitalists make decisons? NBER Working Paper Series, No. 22587 2016. https://medium.com/vcdium/venture-capital-decision-making-c3258bc1b09c. Accessed 2 April 2018.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Bridgham, K., Chandawarkar, A., Darrach, H., Sacks, J.M. (2019). How to Overcome the Valley of Death from Basic Science to Clinical Trials. In: Duscher, D., Shiffman, M.A. (eds) Regenerative Medicine and Plastic Surgery. Springer, Cham. https://doi.org/10.1007/978-3-030-19958-6_20
Download citation
DOI: https://doi.org/10.1007/978-3-030-19958-6_20
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-19957-9
Online ISBN: 978-3-030-19958-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)